Roche’s Genetech announces data from Phase III OUtMATCH study

Genentech, a member of the Roche (RHHBY) Group, announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health-sponsored Phase III OUtMATCH study, which provide further evidence supporting the role of Xolair for the treatment of one or more food allergies. Stage 2 of the OUtMATCH study showed Xolair was more effective with fewer side effects than multi-allergen oral immunotherapy in the first-ever head-to-head trial comparing the two treatment approaches. OIT involves ingesting the food allergen, initially with a very small amount and gradually increasing the amount. These findings were largely driven by the high rates of adverse events leading to study discontinuation in the OIT-treated group.